C Paul
Overview
Explore the profile of C Paul including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
590
Citations
6572
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Quiles-Tsimaratos N, Paul C, De La Brassinne M, Telle-Sauvant H, Corgibet-Escallier F, Tanasescu S, et al.
Ann Dermatol Venereol
. 2022 Jul;
150(1):28-34.
PMID: 35787804
Objectives: Topical maintenance therapy strategy with regard to patients with mild-to-moderate plaque psoriasis (PP) continues to be heterogeneous and insufficiently investigated in real-life clinical practice. The objective of this study...
12.
Stander S, Yosipovitch G, Lacour J, Legat F, Paul C, Reich A, et al.
J Eur Acad Dermatol Venereol
. 2022 Jun;
36(10):1820-1825.
PMID: 35766128
Background: Patients with prurigo nodularis (PN) have multiple itchy nodules, impaired quality of life and sleep deprivation. Prurigo nodularis patients have a high burden of disease, primarily due to the...
13.
Richard M, Paul C, Nijsten T, Gisondi P, Salavastru C, Taieb C, et al.
J Eur Acad Dermatol Venereol
. 2022 Mar;
36(7):1088-1096.
PMID: 35274366
Background: The assessment of the prevalence of diseases is of primary importance in planning health policies. No complete data on the prevalence of skin diseases across European countries are available....
14.
Dumache R, Enache A, Cut T, Paul C, Mihailescu A, Ionescu A, et al.
Clin Lab
. 2022 Mar;
68(3).
PMID: 35254021
Background: The SARS-CoV-2 outbreak started in March 2020 with more than 120,552,261 cases at present and having caused over 2,667,248 deaths worldwide at the time this paper was written. The...
15.
Salomon G, Severino M, Casassa E, Bulai Livideanu C, Meyer N, Lamant L, et al.
Ann Dermatol Venereol
. 2022 Feb;
149(2):139-141.
PMID: 35115205
No abstract available.
16.
van Ee I, Deprez E, Egeberg A, Augustin M, Conrad C, Corazza V, et al.
J Eur Acad Dermatol Venereol
. 2021 Nov;
36(3):403-412.
PMID: 34816508
Background: Physician-reported clinical outcome and quality of life (QoL) measures are currently used to assess outcomes and direct treatment of plaque psoriasis. However, people with psoriasis may have different criteria...
17.
Thyssen J, Yosipovitch G, Paul C, Kwatra S, Chu C, DiBonaventura M, et al.
J Eur Acad Dermatol Venereol
. 2021 Nov;
36(3):434-443.
PMID: 34779063
Background: In JADE COMPARE, abrocitinib improved severity of atopic dermatitis (AD) and demonstrated rapid itch relief. Objectives: We examined clinically meaningful improvements in selected patient-reported outcomes (PROs). Methods: JADE COMPARE...
18.
Kundnani N, Tirziu R, Borza C, Tirziu C, Sharma A, Rosca C, et al.
Eur Rev Med Pharmacol Sci
. 2021 Jul;
25(12):4283-4288.
PMID: 34227063
Objective: The use of current surgical techniques in the management of skin cancers that are not amenable to other treatment options has become the cornerstone of dermatological surgical intervention. Among...
19.
Beylot-Barry M, Seneschal J, Tran D, Bachelez H, Beneton N, Dupuy A, et al.
Br J Dermatol
. 2021 Jun;
185(5):1052-1054.
PMID: 34128543
No abstract available.
20.
Wollenberg A, Nakahara T, Maari C, Peris K, Lio P, Augustin M, et al.
J Eur Acad Dermatol Venereol
. 2021 Apr;
35(7):1543-1552.
PMID: 33834521
Background: Baricitinib is an oral, selective, reversible Janus kinase 1/2 inhibitor approved in the European Union and Japan and under investigation in the United States for treatment of atopic dermatitis...